← Back to Screener
IceCure Medical Ltd. Ordinary Shares (ICCM)
Price$4.37
Value ScoreB
Growth ScoreC
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-87.76%
Price vs S&P 500 (4W)-39.37%
VGM Score39.31
Market Capitalization$12.85M
All Metrics
Book Value / Share (Quarterly)$0.10
P/TBV (Annual)1.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.03%
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-84.31%
Gross Margin (TTM)36.55%
Net Profit Margin (TTM)-441.60%
EPS (TTM)$-0.23
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.23
Revenue Growth (5Y)-2.68%
EPS (Annual)$-0.24
ROI (Annual)-166.36%
Gross Margin (Annual)36.28%
Net Profit Margin (5Y Avg)-430.69%
Cash / Share (Quarterly)$0.10
Revenue Growth QoQ (YoY)25.66%
ROA (Last FY)-108.42%
Revenue Growth TTM (YoY)8.92%
EBITD / Share (TTM)$-0.23
ROE (5Y Avg)-122.46%
Operating Margin (TTM)-439.94%
Cash Flow / Share (Annual)$-0.20
P/B Ratio1.51x
P/B Ratio (Quarterly)2.88x
Net Income / Employee (Annual)$-224,700
EV / Revenue (TTM)1.33x
Net Interest Coverage (TTM)-69.75x
ROA (TTM)-119.13%
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)2.61x
Quick Ratio (Quarterly)1.75x
3-Month Avg Trading Volume0.03M
52-Week Price Return-85.52%
Revenue / Employee (TTM)$53,200
Tangible BV / Share (Quarterly)$0.48
P/S Ratio (Annual)3.80x
Asset Turnover (Annual)0.24x
52-Week High$42.00
Operating Margin (5Y Avg)-436.51%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)-30.37%
26-Week Price Return-79.84%
Quick Ratio (Annual)1.96x
13-Week Price Return-77.66%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.52x
Enterprise Value$4.74M
Revenue / Share Growth (5Y)-25.14%
Asset Turnover (TTM)0.27x
Revenue / Employee (Annual)$50,400
Inventory Turnover (Annual)0.93x
Pretax Margin (Annual)-445.61%
Cash / Share (Annual)$0.12
3-Month Return Std Dev131.44%
Gross Margin (5Y Avg)44.14%
Net Income / Employee (TTM)$-235,000
ROE (Last FY)-166.36%
Net Interest Coverage (Annual)-153.74x
EPS Basic Excl Extra (Annual)$-0.24
Receivables Turnover (TTM)12.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.23
Receivables Turnover (Annual)12.24x
ROI (TTM)-198.32%
P/S Ratio (TTM)3.61x
Pretax Margin (5Y Avg)-430.69%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-109.89%
Year-to-Date Return-76.15%
5-Day Price Return-27.61%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-81.28%
Net Profit Margin (Annual)-445.61%
Month-to-Date Return-33.56%
Cash Flow / Share (TTM)$-0.41
EBITD / Share (Annual)$-0.23
Operating Margin (Annual)-446.70%
ROI (5Y Avg)-122.46%
EPS Basic Excl Extra (TTM)$-0.23
P/TBV (Quarterly)1.53x
P/B Ratio (Annual)4.63x
Inventory Turnover (TTM)0.97x
Pretax Margin (TTM)-441.60%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)-85.92%
Beta1.65x
Revenue / Share (TTM)$0.05
ROE (TTM)-211.73%
52-Week Low$3.75
vGradeB
gGradeC
mGradeF
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.06est. -0.05
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.11
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ICCMIceCure Medical Ltd. Ordinary Shares | B | C | F | $4.37 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Icecure Medical develops minimally invasive cryoablation systems using liquid nitrogen to treat solid tumors across multiple indications, including breast, lung, kidney, and bone cancers. The company's technology offers patients an alternative to traditional surgical intervention with reduced recovery time and lower risk. As a commercial-stage company, Icecure is focused on expanding adoption of its cryoablation platform across oncology markets.